Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

"Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes" was originally created and published by Clinical ...

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, targets a different hormone called amylin, lost as much as 20% weight.

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with or without type 2 diabetes, a pair of phase IIIa trials found. This ...

Nov 8 (Reuters) - Amylin Pharmaceuticals Inc is ending its nearly decade-long diabetes partnership with Eli Lilly and Co, potentially paying up to $1.6 billion to take back rights to its drugs and ...

SAN DIEGO and INDIANAPOLIS, Nov. 8, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) ("Amylin") and Eli Lilly and Company (NYSE: LLY) ("Lilly") today announced an agreement to ...

Eli Lilly and Co., under pressure to gain new products after setbacks this month with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc. or covet companies with more ...

NEW YORK (Reuters) - A long-awaited experimental diabetes medicine from Eli Lilly & Co and Amylin Pharmaceuticals Inc that patients need to inject only once a week failed to match up to a rival ...

Amylin Pharmaceuticals Inc. suffered a setback Wednesday when the Food and Drug Administration said it wouldn’t approve the company’s experimental diabetes drug without additional information. The San ...

Amylin Pharmaceuticals and Eli Lilly today said their diabetes drug Byetta worked better at reducing blood-sugar levels following a meal compared with Merck's Januvia. The results, based on a a ...